Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | FABP6 | P51161 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104713 | 1.00 | TP53 (0.39) | TP53TSHRSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL12384404 | 1.00 | TP53 (0.39) | TP53TSHRSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL24619078 | 0.88 | TSHR (0.45) | TSHRALDH1A1MAPK1FABP6NPSR1 | |
| SCHEMBL9917274 | 0.88 | TSHR (0.45) | TSHRALDH1A1MAPK1FABP6NPSR1 | |
| SCHEMBL1104697 | 0.87 | TP53 (0.46) | TP53TSHRSMN1; SMN2ALDH1A1ATM | |
| SCHEMBL29333971 | 0.86 | ALDH1A1 (0.42) | TSHRALDH1A1MAPK1ATMFABP6 | |
| SCHEMBL15177622 | 0.82 | PAX8 (0.32) | TP53TSHRALDH1A1ATM | |
| SCHEMBL12947486 | 0.82 | KDM4E (0.37) | TP53TSHRSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL25456270 | 0.82 | EPHX2 (0.33) | ALDH1A1CYP2D6KCNH2HRH3ACLY | |
| SCHEMBL8239122 | 0.82 | CYP2D6 (0.32) | ALDH1A1CYP2D6KCNH2HRH3ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES INC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3722298-B1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC (KR) | 2023-08-02 | — | — | EP | disclosed |
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2022-11-15 | — | — | US | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORTION | 2021-06-24 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE HOLDINGS CORPORATION (US) | 2017-07-27 | — | — | US | disclosed |
| US-9624241-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160168141-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-9227985-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| US-9115101-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168141-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | TP53 3610/4885TSHR 178/4885SMN1; SMN2 3342/4885 |
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | TP53 596/4885TSHR 3305/4885SMN1; SMN2 4648/4885 |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | TP53 243/4885TSHR 1769/4885SMN1; SMN2 4604/4885 |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | TP53 3610/4885TSHR 178/4885SMN1; SMN2 3342/4885 |
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | TP53 379/4885TSHR 1771/4885SMN1; SMN2 4578/4885 |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | TP53 379/4885TSHR 1771/4885SMN1; SMN2 4578/4885 |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | TP53 3021/4885TSHR 2547/4885SMN1; SMN2 375/4885 |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | TP53 3700/4885TSHR 317/4885SMN1; SMN2 3727/4885 |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | HSD17B1, HSD17B13, HSD17B11 | TP53 3063/4885TSHR 2638/4885SMN1; SMN2 2284/4885 |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | TP53 3593/4885TSHR 174/4885SMN1; SMN2 3309/4885 |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | TP53 243/4885TSHR 1769/4885SMN1; SMN2 4604/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | TP53 2038/4885TSHR 2669/4885SMN1; SMN2 432/4885 |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | TP53 379/4885TSHR 1771/4885SMN1; SMN2 4578/4885 |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | TP53 379/4885TSHR 1771/4885SMN1; SMN2 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.